Roles of PCSK9 in the Pathogenesis of Periodontal Disease


Cite item

Full Text

Abstract

:Proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors are FDA-approved drugs recommended for high-risk patients with LDL-cholesterol (LDL-c) levels ≥ 70 mg/dl. Several studies have also investigated the relationship between PCSK9 and periodontitis. Specifically, studies have investigated the association between periodontitis and periodontal PCSK9 levels in humans, and periodontium status in PCSK9-knockout versus wild-type mice. While a positive association between periodontitis and periodontal PCSK9 levels has been noted, the findings on the comparison of periodontium status between PCSK9-knockout and wild-type mice have been inconsistent. Different methodologies among these studies may explain this discrepancy. Future experimental studies on the impact of pharmacological PCSK9 inhibition on periodontal status as well as observational studies comparing periodontium status between patients receiving PCSK9 inhibitors and those receiving other lipid-lowering drugs will shed light on the role of PCSK9 in periodontal health and disease.

About the authors

Motahareh Khosrojerdi

Department of Internal Medicine, University Hospital Center Zagreb

Email: info@benthamscience.net

Željko Reiner

Department of Internal Medicine, University Hospital Center Zagreb

Email: info@benthamscience.net

Negin Vatanparast

Dental Research Center, Mashhad Dental School, Mashhad University of Medical Sciences

Email: info@benthamscience.net

Tannaz Jamialahmadi

Applied Biomedical Research Cente, Mashhad University of Medical Sciences

Email: info@benthamscience.net

Prashant Kesharwani

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard

Email: info@benthamscience.net

Amirhossein Sahebkar

Applied Biomedical Research Center, Mashhad University of Medical Sciences

Author for correspondence.
Email: info@benthamscience.net

References

  1. Rosenson, R.S.; Hegele, R.A.; Fazio, S.; Cannon, C.P. The evolving future of PCSK9 inhibitors. J. Am. Coll. Cardiol., 2018, 72(3), 314-329. doi: 10.1016/j.jacc.2018.04.054 PMID: 30012326
  2. Jia, X.; Al Rifai, M.; Saeed, A.; Ballantyne, C.M.; Virani, S.S. PCSK9 inhibitors in the management of cardiovascular risk: A practical guidance. Vasc. Health Risk Manag., 2022, 18, 555-566. doi: 10.2147/VHRM.S275739 PMID: 35898405
  3. Sahebkar, A.; Watts, G.F. New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin. Ther., 2013, 35(8), 1082-1098. doi: 10.1016/j.clinthera.2013.06.019 PMID: 23932550
  4. Zijlstra, L.E.; Mooijaart, S.P.; Jukema, J.W. PCSK9 inhibition in high-risk patients. Aging., 2019, 11(23), 10791-10792. doi: 10.18632/aging.102621 PMID: 31829977
  5. Cesaro, A.; Bianconi, V.; Gragnano, F.; Moscarella, E.; Fimiani, F.; Monda, E.; Scudiero, O.; Limongelli, G.; Pirro, M.; Calabrò, P. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. Biofactors., 2020, 46(3), 367-380. doi: 10.1002/biof.1619 PMID: 31999032
  6. Macchi, C.; Ferri, N.; Sirtori, C.R.; Corsini, A.; Banach, M.; Ruscica, M. Proprotein convertase subtilisin/kexin type 9. Am. J. Pathol., 2021, 191(8), 1385-1397. doi: 10.1016/j.ajpath.2021.04.016 PMID: 34019847
  7. Jamialahmadi, T.; Panahi, Y.; Safarpour, M.A.; Ganjali, S.; Chahabi, M.; Reiner, Z.; Solgi, S.; Vahedian-azimi, A.; Kianpour, P.; Banach, M.; Sahebkar, A. Association of serum PCSK9 levels with antibiotic resistance and severity of disease in patients with bacterial infections admitted to intensive care units. J. Clin. Med., 2019, 8(10), 1742. doi: 10.3390/jcm8101742 PMID: 31635200
  8. Mahboobnia, K.; Pirro, M.; Marini, E.; Grignani, F.; Bezsonov, E.E.; Jamialahmadi, T.; Sahebkar, A. PCSK9 and cancer: Rethinking the link. Biomed. Pharmacother., 2021, 140, 111758. doi: 10.1016/j.biopha.2021.111758 PMID: 34058443
  9. Momtazi-Borojeni, A.A.; Sabouri-Rad, S.; Gotto, A.M., Jr; Pirro, M.; Banach, M.; Awan, Z.; Barreto, G.E.; Sahebkar, A. PCSK9 and inflammation: A review of experimental and clinical evidence. Eur. Heart J. Cardiovasc. Pharmacother., 2019, 5(4), 237-245. doi: 10.1093/ehjcvp/pvz022 PMID: 31236571
  10. Kassebaum, N.J.; Bernabé, E.; Dahiya, M.; Bhandari, B.; Murray, C.J.L.; Marcenes, W. Global burden of severe periodontitis in 1990-2010: A systematic review and meta-regression. J. Dent. Res., 2014, 93(11), 1045-1053. doi: 10.1177/0022034514552491 PMID: 25261053
  11. Thermos, G.; Tosios, K.I. Gingival ischemia and petechiae in a patient medicated with PCSK9 inhibitor for hypercholesterolemia: An adverse drug event? Clinic. Adv. Periodontics., 2019, 9(1), 20-23. doi: 10.1002/cap.10043 PMID: 31490035
  12. Tabeta, K.; Hosojima, M.; Nakajima, M.; Miyauchi, S.; Miyazawa, H.; Takahashi, N.; Matsuda, Y.; Sugita, N.; Komatsu, Y.; Sato, K.; Ishikawa, T.; Akiishi, K.; Yamazaki, K.; Kato, K.; Saito, A.; Yoshie, H. Increased serum PCSK9, a potential biomarker to screen for periodontitis, and decreased total bilirubin associated with probing depth in a Japanese community survey. J. Periodontal Res., 2018, 53(3), 446-456. doi: 10.1111/jre.12533 PMID: 29516504
  13. Rughwani, R.R.; Cholan, P.K.; Victor, D.J.; Ilango, P.; Cherian, S.M.; Rughwani, R.N.; Tadepalli, A. Evaluation of serum and salivary PCSK9 and IL6 and its association with periodontal inflammation and atherosclerotic cardiovascular diseases. J. Oral Biol. Craniofac. Res., 2022, 12(5), 633-638. doi: 10.1016/j.jobcr.2022.08.013 PMID: 36042970
  14. Yokoji-Takeuchi, M.; Tabeta, K.; Takahashi, N.; Arimatsu, K.; Miyazawa, H.; Matsuda-Matsukawa, Y.; Sato, K.; Yamada, M.; Yamazaki, K. Indirect regulation of PCSK9 gene in inflammatory response by Porphyromonas gingivalis infection. Heliyon., 2019, 5(1), e01111. doi: 10.1016/j.heliyon.2018.e01111 PMID: 30671557
  15. Miyazawa, H.; Honda, T.; Miyauchi, S.; Domon, H.; Okui, T.; Nakajima, T. Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration. Clin Chim Acta., 2012, 413(1-2), 154-159. doi: 10.1016/j.cca.2011.09.023
  16. Miyazawa, H.; Tabeta, K.; Miyauchi, S.; Aoki-Nonaka, Y.; Domon, H.; Honda, T.; Nakajima, T.; Yamazaki, K. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice. Lipids Health Dis., 2012, 11(1), 121. doi: 10.1186/1476-511X-11-121 PMID: 22992388
  17. Sun, H.L.; Wu, Y.R.; Song, F.F.; Gan, J.; Huang, L.Y.; Zhang, L.; Huang, C. Role of PCSK9 in the development of mouse periodontitis before and after treatment: A double-edged sword. J. Infect. Dis., 2018, 217(4), 667-680. doi: 10.1093/infdis/jix574 PMID: 29294034
  18. Huang, L.; Wu, H.; Wu, Y.; Song, F.; Zhang, L.; Li, Z.; Sun, H.; Huang, C. Pcsk9 knockout aggravated experimental apical periodontitis via LDLR. J. Dent. Res., 2022, 101(1), 83-92. doi: 10.1177/00220345211015128 PMID: 34036816
  19. Baumeister, S.E.; Holtfreter, B.; Reckelkamm, S.L.; Kocher, T.; Alayash, Z.; Ehmke, B. Genotype-driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis. J. Clin. Periodontol., 2022, 50(1), 114-120. PMID: 36054135
  20. Yuan, Y.; Wu, W.; Sun, S.; Zhang, Y.; Chen, Z. PCSK9: A potential therapeutic target for sepsis. J. Immunol. Res., 2020, 2020, 1-8. doi: 10.1155/2020/2687692 PMID: 33123601

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers